TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: MAX-PC scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of positive biopsy cores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Lower PTSD severity at second assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mini‐AQLQ
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of diabetic ketoacidosis (DKA)
Endpoint domain: Adverse events/effects
Primary endpoint: Discontinuation rates due to GI adverse events
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Hand functional status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total airway resistance (as R5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: THI (Tinnitus Handicap Inventory)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cross-sectional area (CSA) of the VL and thigh flexor muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Gene expression level of muscle ring finger 1 (MuRF1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: T25FW worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NHPT worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: normalized brain volume loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tp-e prolongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: QTc increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean percent change in volume and area of scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean score of doctor's satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean score of patients' satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in BMIz units
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receptivity to cigarette advertising
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: olfaction-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ambulation capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time taken to display valid data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in LS, TH, and FN BMDs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participation in work and employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: plasma sTNFR2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasma TNFα levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasma TNFβ levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Psoriasis Area Severity Index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knee joint position sense (JPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HPV vaccine series completion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: POSAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-week relapse rates
Endpoint domain: Mortality/survival
Primary endpoint: >=50% IEF reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: <=1 leak per 3 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GAIS score mean difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: examination stress scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 3-, 5-, and 8-year CSS
Endpoint domain: Mortality/survival
Primary endpoint: Composite primary end point rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MDS-UPDRS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative live birth rate (LBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of patients meeting physical activity guideline targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proliferation of Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Cells in S interphase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gene expression of NANOG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: students’ depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: test-related stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: malaria incidence and prevalence
Endpoint domain: Mortality/survival
Primary endpoint: median personnel time to implement rfMDA
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: ad libitum alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum troponin level observed during hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Practical examination scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary function test (FVC, FEV1, FEV1/FVC, PEFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean PAQLQ score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: mean PROMIS scores at 1 month
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: healthcare utilization at 1 year
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: cost at 1 year
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: motivation to wear sunscreen
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: motivation to tan indoors
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: motivation to tan outdoors
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: reductions in negative attitudes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adherence to coaching calls
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Correct preliminary diagnoses on day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic workups completed on day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of laboratory tests done
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: less increase in alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: less increase in marijuana use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: less increase in polydrug use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of Urgency Urinary Incontinence (UUI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posterior corneal HOAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vision-related QOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Postoperative inflammatory reaction levels (CRP, IL-6, TNF-α, CD3+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cephalic presentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: incidence of dizziness, lethargy, ataxia and PHN
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients diagnosed with COVID-19 enrolled
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of contacts/cohabitants of COVID-19 patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of IOP-lowering medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Probability of total success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angiographic in‐scaffold late lumen loss (IS‐LLL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean disease-free survival time
Endpoint domain: Mortality/survival
Primary endpoint: AT recurrence risk
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients without vomiting on day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fentanyl dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nefopam dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug-related readmission within 12 months
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Proportion of patients achieving HbA1c of 6.5% or less
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients achieving HbA1c of 7.0% or less
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Q-TWiST
Endpoint domain: Mortality/survival
Primary endpoint: Safety of VGT-309
Endpoint domain: Adverse events/effects
Primary endpoint: Tumor-to-background ratio (TBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients taking >120 MME/day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥CR rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRD- (10-5) rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥CR+MRD- (10-5) rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily positive affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Accumulated carbonylated proteins levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Protective efficacy against pigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: DOAC adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rates
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: New-onset POAF
Endpoint domain: Adverse events/effects
Primary endpoint: Response rates for EPA 4 g/d
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median PBMC TNF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent decrease in plasma hs-CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: panitumumab-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: skin rash
Endpoint domain: Adverse events/effects
Primary endpoint: AF/AFL
Endpoint domain: Mortality/survival
Primary endpoint: Primary end point risk
Endpoint domain: Mortality/survival
Primary endpoint: Arrhythmic end point risk
Endpoint domain: Mortality/survival
Primary endpoint: PCR-corrected ACPR rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of children still parasitaemic at 72 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cases of severe malaria recorded as serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Pain score during suctioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderately severe to severe cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute peripancreatic fluid collections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: team-based performance score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Movement VAS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICU prolonged length of stay (LOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in HPD (Horizontal Pocket Depth)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAL gain (Clinical Attachment Level gain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in DV (Defect Volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IBS-SSS score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Restricted mean survival time differences
Endpoint domain: Mortality/survival
Primary endpoint: work-related burnout
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Diurnal IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with at least 1 adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of first relapse to illicit opioids
Endpoint domain: Mortality/survival
Primary endpoint: Risk of any relapse to illicit opioids
Endpoint domain: Mortality/survival
Primary endpoint: Amelioration of Cardiac Allograft Vasculopathy (CAV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Seroconversion rate (SCR ≥ 40%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroprotection rate (SPR ≥ 70%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean fold rise in HI titers (≥ 2.5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: change in general self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Duration of viral clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reoperation for infection or healing complications
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement on the TIS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year continuation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Variability in peak plasma concentration and area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy intake (kcal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hemoglobin (g/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Iron levels (μg/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: drain tube output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: total Hb loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total OHIP-14 scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: IDFS event reduction
Endpoint domain: Mortality/survival
Primary endpoint: NEC surgery or death
Endpoint domain: Adverse events/effects
Primary endpoint: requirement of additional intraoperative uterotonics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: incidence of nausea or vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: chronic pain interference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS and ODI scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean plasma ropivacaine values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in depression scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: text message response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of fallen cups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in musculoskeletal pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Self-management ability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: total connectedness scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recovery following HCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: joint symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of oropharyngeal injury
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean MVPA (Moderate to Vigorous Physical Activity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balanced baseline characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased fatness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: increased skeletal muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: basal metabolic rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: quality of vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ability to see comfortably
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccination uptake among adults
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child vaccination according to Polish schedule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance of influenza vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of TEAEs grade ≥3
Endpoint domain: Adverse events/effects
Primary endpoint: Number of infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Microleakage mean score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of whole blood interferon gene signature expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: delayed haemorrhage and readmission
Endpoint domain: Adverse events/effects
Primary endpoint: rotational alignment in distal tibia fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of serum biochemical HA, SOD and catalase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in ESR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum concentrations of CXCL1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum concentrations of CXCL5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum concentrations of CXCL6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum concentrations of TNFSF14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: USN recovery following PA treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfaction with analgesic effect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Minimum Lumen Area (MLA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative OHS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety rates two days post-operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction rates 6 weeks postoperatively
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postischemic myocardial injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: adverse outcome
Endpoint domain: Adverse events/effects
Primary endpoint: severe cerebral palsy
Endpoint domain: Adverse events/effects
Primary endpoint: Bayley‐III motor/cognitive composite score <85
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: FZ-response signature enrichment in blood and sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma insulin concentration AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Worsening of fibrosis on high-resolution computed tomography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes